HENLIUS Shares Surge Afternoon on Progress of Key Cancer Drug Trial in Japan

Stock News05-18

HENLIUS (02696) saw its shares rise over 4% in the afternoon session. At the time of writing, the stock was up 3.19%, trading at HK$69.65 with a turnover of HK$37.252 million.

The increase follows the company's announcement regarding its self-developed innovative anti-PD-1 monoclonal antibody, H drug Hansizhuang® (serplulimab, European brand name: Hetronifly®). The bridging trial in Japan for the first-line treatment of extensive-stage small cell lung cancer has completed patient enrollment.

This bridging trial, designated NCT06812260, aims to evaluate the efficacy and safety of the H drug combined with chemotherapy as a first-line treatment for ES-SCLC in Japanese patients. The study is led by Professor Takayasu Kurata from the Kansai Medical University Hospital.

The data from trial NCT06812260, along with results from the ASTRUM-005 study which supported the drug's approval in China and Europe for ES-SCLC, will form the key clinical evidence for the drug's registration application in the Japanese market. HENLIUS plans to collaborate with its Japanese partner, Eisai, to submit the marketing application during Eisai's 2026 fiscal year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181427267?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181427267","market":"us","top_or_hot":-1,"title":"HENLIUS Shares Surge Afternoon on Progress of Key Cancer Drug Trial in Japan","media":"Stock News","content":"<p>HENLIUS (02696) saw its shares rise over 4% in the afternoon session. At the time of writing, the stock was up 3.19%, trading at HK$69.65 with a turnover of HK$37.252 million.</p>\n<p>The increase follows the company's announcement regarding its self-developed innovative anti-PD-1 monoclonal antibody, H drug Hansizhuang® (serplulimab, European brand name: Hetronifly®). The bridging trial in Japan for the first-line treatment of extensive-stage small cell lung cancer has completed patient enrollment.</p>\n<p>This bridging trial, designated NCT06812260, aims to evaluate the efficacy and safety of the H drug combined with chemotherapy as a first-line treatment for ES-SCLC in Japanese patients. The study is led by Professor Takayasu Kurata from the Kansai Medical University Hospital.</p>\n<p>The data from trial NCT06812260, along with results from the ASTRUM-005 study which supported the drug's approval in China and Europe for ES-SCLC, will form the key clinical evidence for the drug's registration application in the Japanese market. HENLIUS plans to collaborate with its Japanese partner, Eisai, to submit the marketing application during Eisai's 2026 fiscal year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS Shares Surge Afternoon on Progress of Key Cancer Drug Trial in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS Shares Surge Afternoon on Progress of Key Cancer Drug Trial in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-18 14:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) saw its shares rise over 4% in the afternoon session. At the time of writing, the stock was up 3.19%, trading at HK$69.65 with a turnover of HK$37.252 million.</p>\n<p>The increase follows the company's announcement regarding its self-developed innovative anti-PD-1 monoclonal antibody, H drug Hansizhuang® (serplulimab, European brand name: Hetronifly®). The bridging trial in Japan for the first-line treatment of extensive-stage small cell lung cancer has completed patient enrollment.</p>\n<p>This bridging trial, designated NCT06812260, aims to evaluate the efficacy and safety of the H drug combined with chemotherapy as a first-line treatment for ES-SCLC in Japanese patients. The study is led by Professor Takayasu Kurata from the Kansai Medical University Hospital.</p>\n<p>The data from trial NCT06812260, along with results from the ASTRUM-005 study which supported the drug's approval in China and Europe for ES-SCLC, will form the key clinical evidence for the drug's registration application in the Japanese market. HENLIUS plans to collaborate with its Japanese partner, Eisai, to submit the marketing application during Eisai's 2026 fiscal year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1181427267","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181427267","pubTimestamp":1779084413,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) saw its shares rise over 4% in the afternoon session. At the time of writing, the stock was up 3.19%, trading at HK$69.65 with a turnover of HK$37.252 million. The increase follows...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","02696":"复宏汉霖","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"由于日本关键癌症药物试验取得进展，复宏汉霖股价下午飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02696":1},"content_text":"HENLIUS (02696) saw its shares rise over 4% in the afternoon session. At the time of writing, the stock was up 3.19%, trading at HK$69.65 with a turnover of HK$37.252 million.\nThe increase follows the company's announcement regarding its self-developed innovative anti-PD-1 monoclonal antibody, H drug Hansizhuang® (serplulimab, European brand name: Hetronifly®). The bridging trial in Japan for the first-line treatment of extensive-stage small cell lung cancer has completed patient enrollment.\nThis bridging trial, designated NCT06812260, aims to evaluate the efficacy and safety of the H drug combined with chemotherapy as a first-line treatment for ES-SCLC in Japanese patients. The study is led by Professor Takayasu Kurata from the Kansai Medical University Hospital.\nThe data from trial NCT06812260, along with results from the ASTRUM-005 study which supported the drug's approval in China and Europe for ES-SCLC, will form the key clinical evidence for the drug's registration application in the Japanese market. HENLIUS plans to collaborate with its Japanese partner, Eisai, to submit the marketing application during Eisai's 2026 fiscal year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181427267","isCrawlerRequest":true}